A) This statement is incorrect. Erythropoietin-stimulating agents (ESAs) are not used to prevent infections during dialysis. They are used to address anemia by stimulating red blood cell production.

B) This statement is accurate. Erythropoietin-stimulating agents (ESAs) stimulate the bone marrow to produce more red blood cells, addressing anemia commonly associated with chronic kidney disease and dialysis.

C) This statement is incorrect. Erythropoietin-stimulating agents (ESAs) do not reduce the risk of blood clot formation. They are specific to stimulating the production of red blood cells.

D) This statement is incorrect. Erythropoietin-stimulating agents (ESAs) do not enhance kidney function and filtration. They target the production of red blood cells to address anemia associated with ESRD and dialysis.